Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1982 1
1983 6
1984 7
1985 17
1986 20
1987 23
1988 32
1989 34
1990 46
1991 35
1992 40
1993 41
1994 40
1995 53
1996 45
1997 55
1998 53
1999 65
2000 70
2001 74
2002 83
2003 79
2004 53
2005 49
2006 51
2007 51
2008 49
2009 54
2010 45
2011 50
2012 51
2013 58
2014 76
2015 77
2016 66
2017 80
2018 69
2019 72
2020 67
2021 80
2022 70
2023 48
2024 27

Text availability

Article attribute

Article type

Publication date

Search Results

2,030 results

Results by year

Filters applied: . Clear all
Page 1
Neurogenic Rosacea Treatment: A Literature Review.
Ivanic MG, Oulee A, Norden A, Javadi SS, Gold MH, Wu JJ. Ivanic MG, et al. J Drugs Dermatol. 2023 Jun 1;22(6):566-575. doi: 10.36849/JDD.7181. J Drugs Dermatol. 2023. PMID: 37276164 Review.
We performed a systematic search of PubMed database and identified 6 articles meeting inclusion criteria with a total of 37 patients with suspected neurogenic rosacea. Combination treatments with topicals (eg, metronidazole, brimonidine), as well as oral medications includ …
We performed a systematic search of PubMed database and identified 6 articles meeting inclusion criteria with a total of 37 patients with su …
Brimonidine.
Bakheit AH, Alomar AM, Darwish H, Alkahtani HM. Bakheit AH, et al. Profiles Drug Subst Excip Relat Methodol. 2023;48:1-37. doi: 10.1016/bs.podrm.2022.11.001. Epub 2023 Feb 24. Profiles Drug Subst Excip Relat Methodol. 2023. PMID: 37061271
Brimonidine is a highly selective 2-adrenoceptor agonist that lowers intraocular pressure (IOP) by decreasing aqueous humor production and increasing aqueous humor outflow via the uveoscleral route. Brimonidine is used to treat glaucoma and other eye conditions. …
Brimonidine is a highly selective 2-adrenoceptor agonist that lowers intraocular pressure (IOP) by decreasing aqueous humor productio …
S2k guideline: Rosacea.
Clanner-Engelshofen BM, Bernhard D, Dargatz S, Flaig MJ, Gieler U, Kinberger M, Klövekorn W, Kuna AC, Läuchli S, Lehmann P, Nast A, Pleyer U, Schaller M, Schöfer H, Steinhoff M, Schwennesen T, Werner RN, Zierhut M, Reinholz M. Clanner-Engelshofen BM, et al. J Dtsch Dermatol Ges. 2022 Aug;20(8):1147-1165. doi: 10.1111/ddg.14849. Epub 2022 Aug 5. J Dtsch Dermatol Ges. 2022. PMID: 35929658
For symptomatic treatment of persistent centrofacial erythema, the topical vasoconstrictors brimonidine or oxymetazoline can also be used. Systemic therapy is recommended for therapy-resistant and severe forms of rosacea papulopustulosa. ...
For symptomatic treatment of persistent centrofacial erythema, the topical vasoconstrictors brimonidine or oxymetazoline can also be …
Rosacea: An Update in Diagnosis, Classification and Management.
Kang CN, Shah M, Tan J. Kang CN, et al. Skin Therapy Lett. 2021 Jul;26(4):1-8. Skin Therapy Lett. 2021. PMID: 34347259 Free article.
General management includes gentle skin care, sun protection, and trigger avoidance. Evidence-based treatment recommendations include topical brimonidine and oxymetazoline for persistent erythema; topical azelaic acid, ivermectin, metronidazole, minocycline and oral doxycy …
General management includes gentle skin care, sun protection, and trigger avoidance. Evidence-based treatment recommendations include topica …
Post-acne erythema treatment: A systematic review of the literature.
Kalantari Y, Dadkhahfar S, Etesami I. Kalantari Y, et al. J Cosmet Dermatol. 2022 Apr;21(4):1379-1392. doi: 10.1111/jocd.14804. Epub 2022 Feb 3. J Cosmet Dermatol. 2022. PMID: 35076997 Review.
Topical treatments such as oxymetazoline, tranexamic acid, and brimonidine tartrate are promising treatments in reducing PAE lesions. ...
Topical treatments such as oxymetazoline, tranexamic acid, and brimonidine tartrate are promising treatments in reducing PAE l …
Rosacea.
Maor D, Chong AH. Maor D, et al. Aust Fam Physician. 2017;46(5):277-281. Aust Fam Physician. 2017. PMID: 28472572 Free article.
Rosacea First-choice treatments.
[No authors listed] [No authors listed] Prescrire Int. 2017 May;26(182):126-128. Prescrire Int. 2017. PMID: 30730673 Review. No abstract available.
Brimonidine tartrate for the treatment of glaucoma.
Oh DJ, Chen JL, Vajaranant TS, Dikopf MS. Oh DJ, et al. Expert Opin Pharmacother. 2019 Jan;20(1):115-122. doi: 10.1080/14656566.2018.1544241. Epub 2018 Nov 8. Expert Opin Pharmacother. 2019. PMID: 30407890 Review.
Brimonidine tartrate is a commonly used eyedrop for short- and long-term lowering of intraocular pressure. ...Areas covered: The authors review the development of topical alpha-adrenergic agonists, with particular attention to the currently available formulations of …
Brimonidine tartrate is a commonly used eyedrop for short- and long-term lowering of intraocular pressure. ...Areas covered: T …
Difference in vasoconstrictors: oxymetazoline vs. brimonidine.
Okwundu N, Cline A, Feldman SR. Okwundu N, et al. J Dermatolog Treat. 2021 Mar;32(2):137-143. doi: 10.1080/09546634.2019.1639606. Epub 2019 Aug 12. J Dermatolog Treat. 2021. PMID: 31294643 Review.
OBJECTIVE: Topical oxymetazoline and brimonidine are the only medications approved for treating persistent facial erythema of rosacea. This review aims to investigate the efficacy, safety, pharmacodynamics, and pharmacokinetic properties of oxymetazoline and brimonidine …
OBJECTIVE: Topical oxymetazoline and brimonidine are the only medications approved for treating persistent facial erythema of rosacea …
Crossover Randomized Study of Pharmacologic Effects of Ripasudil-Brimonidine Fixed-Dose Combination Versus Ripasudil or Brimonidine.
Tanihara H, Yamamoto T, Aihara M, Koizumi N, Minami H, Kojima S, Isobe T, Kanazawa M, Suganami H; K-232 Clinical Study Group. Tanihara H, et al. Adv Ther. 2023 Aug;40(8):3559-3573. doi: 10.1007/s12325-023-02534-w. Epub 2023 Jun 18. Adv Ther. 2023. PMID: 37330927 Free PMC article. Clinical Trial.
Subjects received twice-daily instillation of RBFC ripasudil brimonidine (group A), ripasudil brimonidine RBFC (group B), or brimonidine RBFC ripasudil (group C). ...Transient morphologic changes in corneal endothelial cells occurred for up to several hours w …
Subjects received twice-daily instillation of RBFC ripasudil brimonidine (group A), ripasudil brimonidine RBFC (group B), or …
2,030 results